We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Test Rules Out Heart Attacks in Chest Pain Patients

By LabMedica International staff writers
Posted on 03 Mar 2015
A blood test administered to patients who present at Accident and Emergency (A&E) departments with chest pain, could significantly reduce the admission rates of patients with heart attack symptoms.

Patients with chest pain make up 10% of A&E attendances and while heart attacks occur in a small segment of these patients and until now, patients have had to wait in hospital for up to 12 hours in order to be certain no evidence of a heart attack could be detected in the blood, with these patients often admitted for monitoring.

Scientists at Bournemouth University (UK) collaborating with international colleagues performed a prospective observational study to evaluate the ability of the Triage Rule-out Using high-Sensitivity Troponin (TRUST) accelerated diagnostic protocol (ADP) to identify low-risk patients with suspected acute coronary syndrome (ACS). More...
Patients with suspected ACS were managed according to the local hospital protocol, which involves risk assessment by emergency department physician staff using the m-Goldman risk score and blood drawn for high-sensitivity troponin (hs-cTnT) at six hours after presentation. As part of the study protocol, blood was also taken at presentation for hs-cTnT analysis.

The fifth generation Roche ELECSYS hs-cTnT assay (Roche, Basel, Switzerland) was used which has a limit of detection (lowest analyte concentration likely to be reliably distinguished from the limit of blank at which detection is feasible) of 5 ng/L, limit of blank (highest apparent analyte concentration expected to be found when replicates of a blank sample containing no analyte are tested) of 3 ng/L, 99th centile of 14 ng/L and 10% coefficient of variation of <10% at 9 ng/L. The primary index test was the TRUST ADP and this defined a patient as “low-risk” if all of the following conditions were satisfied at presentation: a m-Goldman Score of 0 or 1, a non-ischemic electrocardiography (ECG) and a single central laboratory hs-cTnT of less than 14 ng/L at presentation.

In all 964 consenting patients were recruited and 99.6% were successfully monitored for 30 days. The TRUST ADP classified 382/960 (39.8%) of patients as at low risk of fatal or non-fatal AMI, with a sensitivity for identifying AMI of 98.8% and a negative predictive value (NPV) of 99.7% and had a similar diagnostic performance for the secondary outcome measure. By using the limit of detection cut-off value of 5 ng/L for the primary outcome measure (AMI) the sensitivity was 100% and 270/922 (29.3%) of patients were eligible for early discharge. The TRUST ADP identified significantly more patients suitable for immediate discharge at 39.8% versus 29.3% (less than 5 ng/L) and 7.9% (less than 3 ng/L) with a lower false-positive rate for acute myocardial infarction (AMI) detection.

Edward W. Carlton, PhD, the lead author of the study said, “We were really pleased with the findings of the study as we have shown that our simple but novel diagnostic strategy can potentially reduce the increasing burden on hospitals. It is my hope that this diagnostic tool can be used widely within hospitals in the UK to rule out heart attacks, allay the fears of patients and improve productivity within hospitals.” The study was published on February 17, 2015, in the journal Heart.

Related Links:
Bournemouth University
Roche  



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.